Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03683589 · ClinicalTrials.gov registry record
De Novo Lipogenesis in Severity of NAFLD
A clinical trial, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- 49
- Enrollment target
NCT03683589 is a clinical trial that has completed, run by University of Missouri-Columbia. The registered enrollment target is 49 participants.
The verdict
NCT03683589 has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese subjects with low IHTG. The purpose of this study is to directly by measure DNL in human liver tissue and comparing it to liver histological scores from patient biopsies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2020-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03683589
The ClinicalTrials.gov registry entry for NCT03683589 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03683589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03683589 about?
NCT03683589 is a clinical study titled "De Novo Lipogenesis in Severity of NAFLD". NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFL...
What is the current status of trial NCT03683589?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2019-02-01. Estimated completion is 2020-07-31.
Who is sponsoring clinical trial NCT03683589?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.